Related MeSH Hierarchy (4)
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Adenocarcinoma » Carcinoma, Hepatocellular
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Digestive System Neoplasms » Liver Neoplasms » Carcinoma, Hepatocellular
Diseases [C] » Digestive System Diseases [C06] » Digestive System Neoplasms » Liver Neoplasms » Carcinoma, Hepatocellular
Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » Liver Neoplasms » Carcinoma, Hepatocellular
Description
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. MeSH
Hierarchy View
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (59)
Phase 2 Indicated Drugs (177)
antigen pulsed dendritic cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cytokine induced killer cells
autologous natural killer cells
Phase 1 Indicated Drugs (142)
antiangiogenic peptide vaccine therapy
autologous dendritic cells loaded with autologous tumor lysate
autologous dendritic cells pulsed with multiple neoantigen peptides.
autologous genetically modified afpc332 t cells
autologous T cell memory cells
dec-205/ny-eso-1 fusion protein cdx-1401
gpc3 and/or tgfβ targeting car-t cells
hcc antigens-specific cd8+ t lymphocytes
modified vaccinia virus ankara vaccine expressing p53
perflutren protein-type a microspheres (Optison)
personalized neoantigen vaccine
recombinant fowlpox-cea(6d)/tricom vaccine
recombinant oncolytic virus m1
recombinant vesicular stomatitis virus-expressing interferon-beta
Other Experimental Indicated Drugs (42)
Organization Involved with Phase 4 Indications (62)
Beijing Weida Cancer Hospital of Chinese Traditional Medical Sciences
Chinese Academy of Medical Sciences
Fujian Mengchao Hepatobiliary Hospital
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
King Faisal Specialist Hospital
National Cheng Kung University
People's Liberation Army of China
Qidong Gaitianli Medicines Co., Ltd
Organization Involved with Phase 3 Indications (183)
All India Institute of Medical Sciences
Anhui College of Traditional Chinese Medicine
Associazione Italiana per la Ricerca sul Cancro
Azienda Ospedaliera Antonio Cardarelli
Azienda Ospedaliera D Cotugno Hospital of Infectious Diseases
Azienda Sanitaria Rummo, Benevento, Division of Medical Oncology
Badalona Hospital Germans Trias i Pujol
Bangabandhu Sheikh Mujib Medical University
Beijing Shenogen Biomedical Co., Ltd
Biocompatibles International plc
China Academy of Chinese Medical Sciences
Clinical Research Organization, Dhaka, Bangladesh
Clinica Universidad de Navarra
ECOG-ACRIN Cancer Research Group
Evangelischen Diakoniekrankenhaus
French National Agency for Research on AIDS and Viral Hepatitis
General Hospital of Chinese Armed Police Forces
German Federal Ministry of Education and Research
Guangzhou Twelfth People 's Hospital
Indian Council of Medical Research
Innovent Biologics (Suzhou) Co. Ltd.
International Atomic Energy Agency
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Jiaozuo third people's hospital
Jilin Provincial Tumor Hospital
Lishui Country People's Hospital
National Cancer Institute (NCI)
National Hepatology & Tropical Medicine Research Institute
Pingmei Shenma Medical Group General Hospital
Radiation Therapy Oncology Group
Second People's Hospital of Yibin
Shandong Provincial Cancer Hospital
Shanghai Junshi Bioscience Co.,Ltd.
Shenma Medical Group General Hospital
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Singapore Clinical Research Institute
The Central Hospital of Lishui City
The Second People's Hospital of GuangDong Province
University of California, San Francisco
University of Campania Luigi Vanvitelli
University of Electronic Science and Technology of China
University of Naples Frederico II
University of Texas at Houston
Organization Involved with Phase 2 Indications (266)
A2 Healthcare Taiwan Corporation
Aeon Therapeutics (Shanghai) Co., Ltd.
Agency for Science, Technology and Research
Apogee Biotechnology Corporation
Assistance Publique - Hôpitaux de Paris
Big Ten Cancer Research Consortium
Bio-Cancer Treatment International Limited
Bumrungrad International Hospital
CAR-T (Shanghai) Biotechnology Co.,Ltd.
Chao Family Comprehensive Cancer Center
China Three Gorges University, Yichang, China
Chinese Anti-Cancer Association
Chinese University of Hong Kong
Chuan An Biotechnology Co., Ltd.
City of Hope National Medical Center
Commissariat A L'energie Atomique
Eastern Cooperative Oncology Group
Federation Francophone de Cancerologie Digestive
Fibrolamellar Cancer Foundation
Hangzhou Hospital of Traditional Chinese Medicine
Hi-Q Marine Biotech International, Ltd.
Hoosier Cancer Research Network
Hospital Universitario Central de Asturias
Humanity & Health Research Centre
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
ImmunoVaccine Technologies, Inc.
Institut für Klinische Krebsforschung IKF GmbH
Istituto Clinico Humanitas - Rozzano (MI), Italy
Italian Trial in Medical Oncology
Kansai Hepatobiliary Oncology Group (KHBO)
Medizinische Hochschule Hannover
Memorial Sloan-Kettering Cancer Center
National Center for Research Resources (NCRR)
National Comprehensive Cancer Network
National Institutes of Health (NIH)
National University of Singapore
New Mexico Cancer Care Alliance
North Central Cancer Treatment Group
Northeast Ohio Medical University
Northern Institute for Cancer Research Newcastle
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Philipps University of Marburg
Radiological Society of North America
SC Liver Research Consortium, LLC
Shenzhen Hank Bioengineering Institute
Shenzhen Hornetcorn Bio-technology Company, LTD
Shenzhen SiBiono GeneTech Co.,Ltd
Shenzhen Third People's Hospital
Simcere Pharmaceutical Co., Ltd
State University of New York, Buffalo
Sunshine Lake Pharma Co., Ltd.
The Fibrolamellar Cancer Foundation
The University of Texas, Dallas
Université catholique de Louvain
University of Alabama, Birmingham
University of British Columbia
University of California, Davis
University of California, Irvine
University of California, Los Angeles
University of North Carolina at Chapel Hill
University of Southern California
University of Texas, Galveston
University of Texas, San Antonio
Ward Veterans General Hospital, Taipei
Washington University in St. Louis
Organization Involved with Phase 1 Indications (86)
Beijing GD Initiative Cell Therapy Technology Co.，Ltd.
Blueprint Medicines Corporation
Case Western Reserve University
CCF Taussig Cancer Solid Tumor Oncology
Cellular Biomedicine Group Ltd.
Concentrx Pharmaceuticals, Inc.
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Hunan Yongren Medical Innovation Co. Ltd.
Institut National de la Santé Et de la Recherche Médicale, France
Methodist Cancer Center, Houston, Texas
National Kidney and Transplant Institute, Philippines
Provectus Biopharmaceuticals, Inc.
Shanghai University of Traditional Chinese Medicine
Sharp Clinical Oncology Research
Shijiazhuang Pharma Group (CSPC)
Shin Kong Wu Ho-Su Memorial Hospital
Sichuan Huiyang Life Science and Technology Corporation
SignalRX Pharmaceuticals, Inc.
Organization Involved with Other Experimental Indications (18)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
